Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug vericiguat faces new test in tricuspid regurgitation patients

NCT ID NCT07668739

Disease control Sponsor: Daejeon St. Mary's hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug vericiguat can improve right heart function and reduce tricuspid regurgitation in 100 adults with heart failure and reduced pumping ability. Participants take vericiguat daily for 9 months, with regular heart scans and walking tests to measure effects. The goal is to see if it lowers hospitalizations and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vericiguat
What this could lead to
If it works, this could provide a new treatment option for heart failure patients with severe tricuspid regurgitation, potentially reducing hospitalizations and improving quality of life.
What could go wrong
This is a relatively small phase 4 trial (100 participants) testing a drug already approved for heart failure, so the added benefit for this specific condition may be modest or not confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age more than 19 years old 2. right ventricular malfunction confirmed with EKG data or cardiac MRI 3. chronic heart failure with LVEF\<45% 4. Patients Who administrated standard treatment of Heart Failur for over the 4 weeks 5. NTproBNP \>1000, NTproBNP \>1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics) 6. Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram 7. Subject who provided voluntary informed consent to participate in the study 8. Patients who have not been administered vericiguat within the last 6 months Exclusion Criteria: 1. Patients with a systolic blood pressure (SBP) \< 100 mmHg 2. Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors 3. Moderate-to-severe right ventricular (RV) failure requiring surgical intervention 4. Patients who are currently pregnant or of childbearing potential

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systolic heart failure tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HFREF Tricuspid regurgitation (TR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Daejeon St.Mary's Hospital

    Daejeon, 34943, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.